The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituxima...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2011
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062293/
https://ncbi.nlm.nih.gov/pubmed/21239695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-314708
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares